Biozoom Financials

Biozoom Stock Summary

Biozoom competes with Eastman Chemical, Hudson Technologies, AMCON Distributing, Sensient Technologies, and SunOpta. Biozoom, Inc. researches, develops, and licenses technologies relating to the mobile remote collection of biomedical data and bi-lateral diagnostic communication. The company was founded in 2004 and is headquartered in Kassel, Germany. Biozoom is traded on OTC Exchange in the United States.

Biozoom Key Financial Ratios

Generally speaking, Biozoom's financial ratios allow both analysts and investors to convert raw data from Biozoom's financial statements into concise, actionable information that can be used to evaluate the performance of Biozoom over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Biozoom reports annually and quarterly.

Biozoom Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Biozoom's current stock value. Our valuation model uses many indicators to compare Biozoom value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biozoom competition to find correlations between indicators driving Biozoom's intrinsic value. More Info.Biozoom is rated below average in number of employees category among related companies. It is rated below average in beta category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Biozoom by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Biozoom's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biozoom's earnings, one of the primary drivers of an investment's value.

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Biozoom information on this page should be used as a complementary analysis to other Biozoom's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

If you are still planning to invest in Biozoom check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biozoom's history and understand the potential risks before investing.